The GoBroad Medical Forum - The 4th Shanghai Seminar and Training session on Clinical Application of Autologous Hematopoietic Stem Cell Transplantation" was successfully convened in Shanghai on September 7th to 8th, 2024. This event was organized by the National Clinical Research Center for Hematologic Diseases of the Blood Disease Hospital, Chinese Academy of Medical Sciences, and was hosted by the GoBroad Shanghai Zhaxin Hospital/Shanghai Liquan Hospital.

This seminar and training session not only featured a main forum on transplantation, rich in content and full of practical content, but also specially introduced the 2024 GoBroad Hematopoietic Stem Cell Transplantation and Cell Therapy Summit, along with three specialized sub-forums dedicated to lymphoma and myeloma treatment strategies and nursing practices. Over a hundred authoritative experts from across the nation, including leading figures in hematopoietic stem cell transplantation and distinguished scholars in the field of hematology oncology, delivered lectures, sharing their invaluable clinical experiences, research findings, and innovative concepts. Nearly 400 hematologists and nursing professionals convened to engage in an in-depth, multidimensional, and comprehensive discussion on the latest advancements and clinical application challenges in hematopoietic stem cell transplantation technology.

Expert Addresses at the Opening Ceremony

During the opening ceremony, Professor Wang Chun, the Presiding Chairman of the seminar and Medical Director of GoBroad Shanghai Zhaxin Hospital/Shanghai Liquan Hospital, delivered the opening address, and recounted the development journey of the two hospitals, Professor Wang stated, "Since its inception, our team has consistently prioritized patients, relentlessly pursuing innovation and breakthroughs to establish our distinctive approach to diagnosis and treatment! Within less than five years of establishing our two hospitals, we have successfully conducted over 650 hematopoietic stem cell transplants." This milestone not only represents a significant increase in the volume of transplants but also demonstrates the hospital’s bold approach in tackling some of the most challenging cases in hematological oncology. These include: ① Salvage transplants for patients unable to achieve remission, with more than 80% of transplant cases involving non-remission patients; ② Transplants for elderly patients, with those over 60 years old accounting for nearly 22% of cases, and the oldest transplant recipient being 74 years old; ③ Advancements in the transplant treatment of refractory hematologic malignancies, especially hematopoietic stem cell transplantation for myelofibrosis, refractory peripheral T-cell lymphoma, and patients with strongly positive DSA. Concurrently, the team has been actively engaging in academic exchanges, consistently organizing national ASCT forums, quarterly Training session, and discussions on challenging medical cases via Cloud Platform. Through these initiatives, they collaborate with hematologic oncology professionals nationwide to advance China's ASCT technology, foster the development of the hematology field, and improve patient outcomes. Professor Wang Chun also highlighted that ASCT, as an important treatment modality in the realm of hematologic tumors, has garnered growing attention in China in recent years. Despite this, many clinical needs remain unmet. Professor Wang expressed hope that such forums and training sessions would bolster exchange and collaboration among experts and scholars in the field, collectively elevating the application of ASCT in China, standardizing transplant procedures, and serving more clinical patients.

The GoBroad Healthcare Forum concluded with vibrant exchanges. Since its inception, the GoBroad Healthcare Group's Shanghai Zhaxin Hospital/Shanghai Liquan Hospital has been proactively building an ecosystem for academic exchanges, regularly hosting summits and training sessions, and innovatively establishing a "“Cloud Connectivity · Collaboratively Exploring Challenges" platform for case discussions, attracting nearly 3,000 hematologists nationwide. Led by Professor Wang Chun, the expert team combined deep theoretical knowledge with extensive practical experience to engage in profound exchanges and collaborative research with colleagues from various regions. This grand event not only fostered a deep integration of theory and practice but also infused new vitality and momentum into the clinical practice of hematopoietic stem cell transplantation in China. It holds significant importance in promoting academic exchanges, advancing technological progress, enhancing clinical diagnosis and treatment capabilities, and optimizing treatment plans for patients.